Advice
following a full submission:
lusutrombopag (Mulpleo) is accepted for use within NHSScotland.
Indication under review: for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.
In two phase III studies, lusutrombopag was superior to placebo in reducing the need for platelet transfusions in thrombocytopenic patients with chronic liver disease undergoing invasive procedures.
Medicine details
- Medicine name:
- lusutrombopag (Mulpleo)
- SMC ID:
- SMC2227
- Indication:
For the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures.
- Pharmaceutical company
- Shionogi Limited
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 December 2019